Cargando…
CD34 positive cells as endothelial progenitor cells in biology and medicine
CD34 is a cell surface antigen expressed in numerous stem/progenitor cells including hematopoietic stem cells (HSCs) and endothelial progenitor cells (EPCs), which are known to be rich sources of EPCs. Therefore, regenerative therapy using CD34(+) cells has attracted interest for application in pati...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10150654/ https://www.ncbi.nlm.nih.gov/pubmed/37138792 http://dx.doi.org/10.3389/fcell.2023.1128134 |
_version_ | 1785035394123825152 |
---|---|
author | Hassanpour, Mehdi Salybekov, Amankeldi A. Kobayashi, Shuzo Asahara, Takayuki |
author_facet | Hassanpour, Mehdi Salybekov, Amankeldi A. Kobayashi, Shuzo Asahara, Takayuki |
author_sort | Hassanpour, Mehdi |
collection | PubMed |
description | CD34 is a cell surface antigen expressed in numerous stem/progenitor cells including hematopoietic stem cells (HSCs) and endothelial progenitor cells (EPCs), which are known to be rich sources of EPCs. Therefore, regenerative therapy using CD34(+) cells has attracted interest for application in patients with various vascular, ischemic, and inflammatory diseases. CD34(+) cells have recently been reported to improve therapeutic angiogenesis in a variety of diseases. Mechanistically, CD34(+) cells are involved in both direct incorporation into the expanding vasculature and paracrine activity through angiogenesis, anti-inflammatory, immunomodulatory, and anti-apoptosis/fibrosis roles, which support the developing microvasculature. Preclinical, pilot, and clinical trials have well documented a track record of safety, practicality, and validity of CD34(+) cell therapy in various diseases. However, the clinical application of CD34(+) cell therapy has triggered scientific debates and controversies in last decade. This review covers all preexisting scientific literature and prepares an overview of the comprehensive biology of CD34(+) cells as well as the preclinical/clinical details of CD34(+) cell therapy for regenerative medicine. |
format | Online Article Text |
id | pubmed-10150654 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-101506542023-05-02 CD34 positive cells as endothelial progenitor cells in biology and medicine Hassanpour, Mehdi Salybekov, Amankeldi A. Kobayashi, Shuzo Asahara, Takayuki Front Cell Dev Biol Cell and Developmental Biology CD34 is a cell surface antigen expressed in numerous stem/progenitor cells including hematopoietic stem cells (HSCs) and endothelial progenitor cells (EPCs), which are known to be rich sources of EPCs. Therefore, regenerative therapy using CD34(+) cells has attracted interest for application in patients with various vascular, ischemic, and inflammatory diseases. CD34(+) cells have recently been reported to improve therapeutic angiogenesis in a variety of diseases. Mechanistically, CD34(+) cells are involved in both direct incorporation into the expanding vasculature and paracrine activity through angiogenesis, anti-inflammatory, immunomodulatory, and anti-apoptosis/fibrosis roles, which support the developing microvasculature. Preclinical, pilot, and clinical trials have well documented a track record of safety, practicality, and validity of CD34(+) cell therapy in various diseases. However, the clinical application of CD34(+) cell therapy has triggered scientific debates and controversies in last decade. This review covers all preexisting scientific literature and prepares an overview of the comprehensive biology of CD34(+) cells as well as the preclinical/clinical details of CD34(+) cell therapy for regenerative medicine. Frontiers Media S.A. 2023-04-17 /pmc/articles/PMC10150654/ /pubmed/37138792 http://dx.doi.org/10.3389/fcell.2023.1128134 Text en Copyright © 2023 Hassanpour, Salybekov, Kobayashi and Asahara. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Cell and Developmental Biology Hassanpour, Mehdi Salybekov, Amankeldi A. Kobayashi, Shuzo Asahara, Takayuki CD34 positive cells as endothelial progenitor cells in biology and medicine |
title | CD34 positive cells as endothelial progenitor cells in biology and medicine |
title_full | CD34 positive cells as endothelial progenitor cells in biology and medicine |
title_fullStr | CD34 positive cells as endothelial progenitor cells in biology and medicine |
title_full_unstemmed | CD34 positive cells as endothelial progenitor cells in biology and medicine |
title_short | CD34 positive cells as endothelial progenitor cells in biology and medicine |
title_sort | cd34 positive cells as endothelial progenitor cells in biology and medicine |
topic | Cell and Developmental Biology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10150654/ https://www.ncbi.nlm.nih.gov/pubmed/37138792 http://dx.doi.org/10.3389/fcell.2023.1128134 |
work_keys_str_mv | AT hassanpourmehdi cd34positivecellsasendothelialprogenitorcellsinbiologyandmedicine AT salybekovamankeldia cd34positivecellsasendothelialprogenitorcellsinbiologyandmedicine AT kobayashishuzo cd34positivecellsasendothelialprogenitorcellsinbiologyandmedicine AT asaharatakayuki cd34positivecellsasendothelialprogenitorcellsinbiologyandmedicine |